

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): **December 14, 2022**

INTELLIGENT BIO SOLUTIONS INC.
(Exact name of registrant as specified in its charter)

Delaware
(State of Incorporation)

001-39825
(Commission File Number)

82-1512711
(IRS employer identification no.)

142 West, 57th Street, 11th Floor
New York, NY 10019
(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: **(646) 828-8258**

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.01 par value	INBS	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure.

Pursuant to Regulation FD, Intelligent Bio Solutions Inc. (the “Company”) hereby furnishes the presentation (the “Presentation”) that the Company will make available on December 14, 2022, relating to the Company’s business and operations. The Presentation can be accessed by visiting the Investors section of the Company’s website: www.gbs.inc.

The information furnished by the Company pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be deemed to be incorporated by reference into any Company filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

No.	Description
99.1	Presentation made available on December 14, 2022.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 14, 2022

INTELLIGENT BIO SOLUTIONS INC.

By: /s/ Spiro Sakiris

Name: Spiro Sakiris

Title: Chief Financial Officer



Pioneering Painfree Solutions

December 2022

(NASDAQ: INBS)

Legal

Forward Looking Statements

Certain statements in this presentation may constitute "forward-looking" statements as defined in Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), Section 21E of the Securities Exchange Act of 1934 (the "Exchange Act"), the Private Securities Litigation Reform Act of 1995 (the "PSLRA") or in releases made by the Securities and Exchange Commission ("SEC"), all as may be amended from time to time. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of IBS, Inc. and its affiliates ("IBS") or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements that are not historical fact are forward-looking statements. Forward-looking statements can be identified by, among other things, the use of forward-looking language, such as the words "plan," "believe," "expect," "anticipate," "intend," "estimate," "project," "may," "will," "would," "could," "should," "seeks," or "scheduled to," or other similar words, or the negative of these terms or other variations of these terms or comparable language, or by discussion of strategy or intentions. These cautionary statements are being made pursuant to the Securities Act, the Exchange Act and the PSLRA with the intention of obtaining the benefits of the "safe harbor" provisions of such laws.

IBS cautions that any forward-looking statements made by IBS are not guarantees or indicative of future performance. Although IBS believes that its plans, cost estimates, returns on investments, intentions and expectations reflected in or suggested by such forward-looking statements are reasonable, actual results could differ materially from a projection or assumption in any forward-looking statements. IBS's future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties. IBS does not have, nor undertake, any obligation to update or revise any forward-looking statements whether as a result of new information, subsequent events or otherwise, unless otherwise required by law.

These materials are not intended as an offer or solicitation with respect to the purchase or sale of any security and may not be reproduced or redistributed in whole or in part to any other person. Recipients should seek appropriate independent professional advice prior to relying on or entering any commitment based upon materials.

All information included in this presentation is based on continuing operations, unless otherwise noted.

Investment Highlights

IBS Inc. develops non-invasive, real-time drug and point-of-care testing


Pioneering biosensor testing platform adaptable to large markets with multiple applications and indications.




Commercially available and approved fingerprinting drug detection technology makes testing easy (<10 min) and reliable for both the employer and employee.



Saliva Glucose test strip is intended to make blood-based finger pricking to monitor glucose levels obsolete.



Deep pipeline of applications for infectious disease, substance abuse and disease monitoring at POC.



Experienced Management, University Partnerships and Advisory Board members all have deep industry expertise in regulatory approvals, manufacturing as well as Intl sales and marketing.





Product Portfolio

Product Portfolio



Simple, reliable fingerprint drug test

- Fingerprint based drug test
- On site results in 10 minutes
- Commercialized in the U.K.
- Increasing customer base
- Launching in Asia Q1 2023
- Available in the U.S. for forensic use



Biosensor platform for diagnostic test

- R&D at Newcastle University Australia
- Printable Organic Thin Film Transistor
- Saliva Glucose Biosensor undergoing clinal test.
- Point of care testing
- Results under 1 min
- Affordable, non-invasive testing

Intelligent Fingerprinting Platform


Providing a non-invasive, discreet, staff-friendly drug testing solution

3 Steps to
Simpler Drug
Screening




Portable

Our system is compact and portable, for convenient drug screening whenever it's needed, in a variety of locations




Hygienic & Easy to use

Thanks to its non-invasive, non-biohazardous technique, our fingerprint-based drug test is hygienic and simple to administer



Non-invasive & Dignified

Our system works by analyzing fingerprint sweat, so sample collection is non-invasive, simple and dignified



Cost-effective

Our multi-panel tests are quick and easy, with no need for gender-specific collectors, specialist handling or clinical waste disposal



Rapid

Fingerprint sample collection takes seconds and analysis for multiple drugs of abuse is complete in minutes

Biosensor Platform

The Biosensor is a platform technology that can be adapted to 130 different analytes by modifying the top layer.





Figure Above :
Biosensor design (a) cross-section through the sensor at the source-drain channel region parallel to the channel length; (b) cross-section through the center of the device perpendicular to the channel length.



The core architecture of the Biosensor is patented Organic Thin Film Transistor (OTFT) technology, **which can be printed at scale, at a low cost.**



The Company has identified a pipeline of up to **130 different analytes.**



The Biosensor exhibits a linear glucose response at concentrations **100 times more sensitive** than commercial blood glucose sensors¹.



The top layer of the Biosensor is **easily modified** to detect a range of analytes. By substituting the detection element of the Biosensor, depending on the analyte to be detected, the Biosensor can monitor a wide range of saliva-based diagnostic analytes (e.g., glucose oxidase for monitoring glucose in saliva).

¹ Elkington, D., Belcher, W.J., Dastoor, P.C. & Zhou, X.J., 2014, 'Detection of saliva-range glucose concentrations using organic thin-film transistors', *Applied Physics Letters*, 105, 043303. 10.1063/1.4892012.

Intellectual Property



12 worldwide patent family applications

- 12 granted across 45 territories
- A further 11 territories pending



Covering all aspects of fingerprint diagnostics

- Chemistry
- Screening cartridge technology
- Collection cartridge technology
- Fingerprint quantitation
- Fingerprint controlled medication dispenser
- Lab testing of fingerprints
- Accessories
- Lateral flow test strip reader



Supported by design registrations, trademarks & know-how






Market Opportunity

Leveraging Intelligent non-invasive diagnostic testing to address current global demands

Global Drug Screening Market

Global Drug Screening Market to Reach \$11.6B Billion by 2026¹



Customer Segments		
<input type="checkbox"/> Drug testing Labs	<input type="checkbox"/> Schools/Colleges	<input type="checkbox"/> Mining
<input type="checkbox"/> Workplaces	<input type="checkbox"/> Pain Management Centres	<input type="checkbox"/> Construction
<input type="checkbox"/> Criminal Justice	<input type="checkbox"/> Transportations	<input type="checkbox"/> Military
<input type="checkbox"/> Law enforcements		<input type="checkbox"/> Individual users

Global Diabetes Market

Market Facts and Figures¹



The total number of people with diabetes is predicted to rise to **643 million** (1 in 9 adults) by 2030 and **784 million** (1 in 8 adults) by 2045.



537 million adults (20-79 years) are living with diabetes worldwide - 1 in 10.



4 in 5 people with diabetes (81%) live in low income and middle-income countries.



Diabetes was responsible for an estimated **\$966 billion** in global health expenditure in 2021. This represents a **316%** increase over the last 15 years.



Diabetes caused **6.7 million** deaths in 2021 - 1 every 5 seconds.



541 million adults worldwide, or **1 in 10**, have impaired glucose tolerance, placing them at high risk of developing type 2 diabetes.




An estimated 44% of adults living with diabetes (**240 million people**) are undiagnosed. Almost 90% of these people live in low income and middle-income countries.



68% of adults with diabetes live in the 10 countries with the highest number of people with diabetes.

Achievements and Team

Completed & Anticipated Milestones




Leadership Team Bios



Dr. Steven Boyages
M.D., MB, BS, Ph.D.
Chairman of the Board

Dr. Boyages is a practicing clinician in endocrinology with 30+ years' experience in medicine, including multiple executive positions.



Harry Simeonidis
CEO - IBS

Mr. Simeonidis has over 25 years' experience in global management roles in healthcare, pharmaceutical and life science businesses. Former CEO of GE Healthcare ANZ and General Manager for Surgery APAC.



Spiro Sakiris
CFO - IBS

Mr. Sakiris has 32 years' experience in accounting, taxation, IPOs, capital raising, and business system designs, including the application of IFRS and US GAAP for the life science industry.



Philip Hand
Executive Chairman - IFP

Mr. Hand was instrumental in growing Cozart Bioscience plc into a leading drugs of abuse business, specialising in POCT, primarily using an oral fluid (saliva) sample. Cozart was listed on AIM and sold to Concerto.



Thank You

Leveraging the power of biotechnology
to transform non-invasive diagnostic
testing and improve lives.